Solasia Pharma K.K. announced that WEP Clinical LTD (a UK- & US-based company, hereinafter "WEP"), have commenced a Named Patient Program (NPP) for DARVIAS® Injection 135 mg, anti-tumor agents /Organoarsenic compound [generic name: darinaparsin] (hereinafter " DARVIAS® "), a treatment for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter "PTCL"). DARVIAS® is an anti-cancer agent with a novel mechanism of action, which was approved and launched in Japan in 2022 for relapsed or refractory PTCL. The NPP is designed to ensure that physicians in Europe and other regions around the world, where DARVIAS® is not commercially available, can request DARVIAS® on behalf of individual patients who need a new treatment option in PTCL.